Recent submissions

  • Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team. 

    Nanton, V; Appleton, R; Dale, J; Roscoe, J; Hamborg, T; Ahmedzai, SH; Arvanitis, TN; Badger, D; James, N; Mendelsohn, R; Khan, O; Parashar, D; Patel, P (2017-07-28)
    BACKGROUND:The potential of technology to aid integration of care delivery systems is being explored in a range of contexts across a variety of conditions in the United Kingdom. Prostate cancer is the most common cancer ...
  • Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. 

    Ward, DG; Gordon, NS; Boucher, RH; Pirrie, SJ; Baxter, L; Ott, S; Silcock, L; Whalley, CM; Stockton, JD; Beggs, AD; Griffiths, M; Abbotts, B; Ijakipour, H; Latheef, FN; Robinson, RA; White, AJ; James, ND; Zeegers, MP; Cheng, KK; Bryan, RT (2019-09)
    OBJECTIVES:To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the ...
  • Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. 

    Hague, D; Townsend, S; Masters, L; Rauchenberger, M; Van Looy, N; Diaz-Montana, C; Gannon, M; James, N; Maughan, T; Parmar, MKB; Brown, L; Sydes, MR; STAMPEDE and FOCUS4 investigators (2019-05-29)
    BACKGROUND:There is limited research and literature on the data management challenges encountered in multi-arm, multi-stage platform and umbrella protocols. These trial designs allow both (1) seamless addition of new ...
  • Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. 

    Haddad, R; Cohen, EEW; Venkatachalam, M; Young, K; Singh, P; Shaw, JW; Korytowsky, B; Abraham, P; Harrington, KJ (2020-01-29)
    Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model ...
  • Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. 

    Close, HJ; Stead, LF; Nsengimana, J; Reilly, KA; Droop, A; Wurdak, H; Mathew, RK; Corns, R; Newton-Bishop, J; Melcher, AA; Short, SC; Cook, GP; Wilson, EB (2020-04)
    Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed as weakly immunogenic, GBM responds poorly to current immunotherapies. To understand this problem more clearly we used a combination ...
  • Combination therapy with oncolytic viruses and immune checkpoint inhibitors. 

    Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; Bozhanova, G; Patin, EC; McLaughlin, M; Mansfield, D; Baker, G; Grove, L; Pedersen, M; Kyula, J; Roulstone, V; Wilkins, A; McDonald, F; Harrington, K; Melcher, A (2020-02-23)
    Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ...
  • Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. 

    Terrisse, S; Karamouza, E; Parker, CC; Sartor, AO; James, ND; Pirrie, S; Collette, L; Tombal, BF; Chahoud, J; Smeland, S; Erikstein, B; Pignon, J-P; Fizazi, K; Le Teuff, G; MORPHEP Collaborative Group (2019-12-12)
    Importance:Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has ...
  • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

    James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
    IMPORTANCE:The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

    James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
    BACKGROUND:Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
  • Magnetic resonance imaging sequence evaluation of an MR Linac system; early clinical experience. 

    Eccles, CL; Adair Smith, G; Bower, L; Hafeez, S; Herbert, T; Hunt, A; McNair, HA; Ofuya, M; Oelfke, U; Nill, S; Huddart, RA; PRIMER TMG (2019-12-16)
    Objectives:To systematically identify the preferred magnetic resonance imaging (MRI) sequences following volunteer imaging on a 1.5 Tesla (T) MR-Linear Accelerator (MR Linac) for future protocol development. Methods:Non-patient ...
  • Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. 

    Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Chen, Y; Connor, AE; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Larsson, SC; Linet, M; Ma, H; Milne, RL; Ozasa, K; Palmer, JR; Riboli, E; Rohan, TE; Sacerdote, C; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2020-02-03)
    Early-adulthood body size is strongly inversely associated with risk of premenopausal breast cancer. It is unclear whether subsequent changes in weight affect risk. We pooled individual-level data from 17 prospective studies ...
  • Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604). 

    Cafferty, FH; White, JD; Shamash, J; Hennig, I; Stenning, SP; Huddart, RA; TE23 Trial Management Group and Collaborators (2020-03)
    BACKGROUND:Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, ...
  • Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. 

    Callender, T; Emberton, M; Morris, S; Eeles, R; Eeles, R; Kote-Jarai, Z; Pharoah, PDP; Pashayan, N (2019-12-20)
    BACKGROUND:The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of ...
  • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. 

    Fachal, L; Aschard, H; Beesley, J; Barnes, DR; Allen, J; Kar, S; Pooley, KA; Dennis, J; Michailidou, K; Turman, C; Soucy, P; Lemaçon, A; Lush, M; Tyrer, JP; Ghoussaini, M; Moradi Marjaneh, M; Jiang, X; Agata, S; Aittomäki, K; Alonso, MR; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Auber, B; Auer, PL; Azzollini, J; Balmaña, J; Barkardottir, RB; Barrowdale, D; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Białkowska, K; Blanco, AM; Blomqvist, C; Blot, W; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borg, A; Bosse, K; Brauch, H; Brenner, H; Briceno, I; Brock, IW; Brooks-Wilson, A; Brüning, T; Burwinkel, B; Buys, SS; Cai, Q; Caldés, T; Caligo, MA; Camp, NJ; Campbell, I; Canzian, F; Carroll, JS; Carter, BD; Castelao, JE; Chiquette, J; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Cybulski, C; Czene, K; Daly, MB; de la Hoya, M; Devilee, P; Diez, O; Ding, YC; Dite, GS; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Droit, A; Dubois, S; Dumont, M; Duran, M; Durcan, L; Dwek, M; Eccles, DM; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Fletcher, O; Floris, G; Flyger, H; Foretova, L; Foulkes, WD; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Gago-Dominguez, M; Gambino, G; Ganz, PA; Gapstur, SM; Garber, J; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Tibiletti, MG; Greene, MH; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hartikainen, JM; Hartman, M; He, W; Healey, CS; Heemskerk-Gerritsen, BAM; Heyworth, J; Hillemanns, P; Hogervorst, FBL; Hollestelle, A; Hooning, MJ; Hopper, JL; Howell, A; Huang, G; Hulick, PJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Isaacs, C; Iwasaki, M; Jager, A; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kang, D; Kapoor, PM; Karlan, BY; Keeman, R; Kerin, MJ; Khusnutdinova, E; Kiiski, JI; Kirk, J; Kitahara, CM; Ko, Y-D; Konstantopoulou, I; Kosma, V-M; Koutros, S; Kubelka-Sabit, K; Kwong, A; Kyriacou, K; Laitman, Y; Lambrechts, D; Lee, E; Leslie, G; Lester, J; Lesueur, F; Lindblom, A; Lo, W-Y; Long, J; Lophatananon, A; Loud, JT; Lubiński, J; MacInnis, RJ; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Matsuo, K; Maurer, T; Mavroudis, D; Mayes, R; McGuffog, L; McLean, C; Mebirouk, N; Meindl, A; Miller, A; Miller, N; Montagna, M; Moreno, F; Muir, K; Mulligan, AM; Muñoz-Garzon, VM; Muranen, TA; Narod, SA; Nassir, R; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nikitina-Zake, L; Norman, A; Offit, K; Olah, E; Olopade, OI; Olsson, H; Orr, N; Osorio, A; Pankratz, VS; Papp, J; Park, SK; Park-Simon, T-W; Parsons, MT; Paul, J; Pedersen, IS; Peissel, B; Peshkin, B; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Prajzendanc, K; Prentice, R; Presneau, N; Prokofyeva, D; Pujana, MA; Pylkäs, K; Radice, P; Ramus, SJ; Rantala, J; Rau-Murthy, R; Rennert, G; Risch, HA; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sánchez-Herrero, E; Sandler, DP; Santamariña, M; Saunders, C; Sawyer, EJ; Scheuner, MT; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schöttker, B; Schürmann, P; Scott, C; Scott, RJ; Senter, L; Seynaeve, CM; Shah, M; Sharma, P; Shen, C-Y; Shu, X-O; Singer, CF; Slavin, TP; Smichkoska, S; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Stoppa-Lyonnet, D; Sutter, C; Swerdlow, AJ; Tamimi, RM; Tan, YY; Tapper, WJ; Taylor, JA; Teixeira, MR; Tengström, M; Teo, SH; Terry, MB; Teulé, A; Thomassen, M; Thull, DL; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Torres-Mejía, G; Troester, MA; Truong, T; Tung, N; Tzardi, M; Ulmer, H-U; Vachon, CM; van Asperen, CJ; van der Kolk, LE; van Rensburg, EJ; Vega, A; Viel, A; Vijai, J; Vogel, MJ; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Wu, AH; Yannoukakos, D; Zhang, Y; Zheng, W; Hunter, D; Pharoah, PDP; Chang-Claude, J; García-Closas, M; Schmidt, MK; Milne, RL; Kristensen, VN; French, JD; Edwards, SL; Antoniou, AC; Chenevix-Trench, G; Simard, J; Easton, DF; Kraft, P; Dunning, AM (2020-01-07)
    Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association ...
  • 3D tumour spheroids for the prediction of the effects of radiation and hyperthermia treatments. 

    Brüningk, SC; Rivens, I; Box, C; Oelfke, U; Ter Haar, G (2020-02-03)
    For multimodality therapies such as the combination of hyperthermia and radiation, quantification of biological effects is key for dose prescription and response prediction. Tumour spheroids have a microenvironment that ...
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

    Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-04)
    BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
  • Dosimetric accuracy of delivering SBRT using dynamic arcs on Cyberknife. 

    Bedford, JL; Nill, S; Oelfke, U (2020-02-12)
    PURPOSE:Several studies have demonstrated potential improvements in treatment time through the use of dynamic arcs for delivery of stereotactic body radiation therapy (SBRT) on Cyberknife. However, the delivery system has ...
  • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. 

    Patel, VL; Busch, EL; Friebel, TM; Cronin, A; Leslie, G; McGuffog, L; Adlard, J; Agata, S; Agnarsson, BA; Ahmed, M; Aittomäki, K; Alducci, E; Andrulis, IL; Arason, A; Arnold, N; Artioli, G; Arver, B; Auber, B; Azzollini, J; Balmaña, J; Barkardottir, RB; Barnes, DR; Barroso, A; Barrowdale, D; Belotti, M; Benitez, J; Bertelsen, B; Blok, MJ; Bodrogi, I; Bonadona, V; Bonanni, B; Bondavalli, D; Boonen, SE; Borde, J; Borg, A; Bradbury, AR; Brady, A; Brewer, C; Brunet, J; Buecher, B; Buys, SS; Cabezas-Camarero, S; Caldés, T; Caliebe, A; Caligo, MA; Calvello, M; Campbell, IG; Carnevali, I; Carrasco, E; Chan, TL; Chu, ATW; Chung, WK; Claes, KBM; Collaborators, GS; Collaborators, E; Cook, J; Cortesi, L; Couch, FJ; Daly, MB; Damante, G; Darder, E; Davidson, R; de la Hoya, M; Puppa, LD; Dennis, J; Díez, O; Ding, YC; Ditsch, N; Domchek, SM; Donaldson, A; Dworniczak, B; Easton, DF; Eccles, DM; Eeles, RA; Ehrencrona, H; Ejlertsen, B; Engel, C; Evans, DG; Faivre, L; Faust, U; Feliubadaló, L; Foretova, L; Fostira, F; Fountzilas, G; Frost, D; García-Barberán, V; Garre, P; Gauthier-Villars, M; Géczi, L; Gehrig, A; Gerdes, A-M; Gesta, P; Giannini, G; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gutierrez-Barrera, AM; Hahnen, E; Hamann, U; Hauke, J; Herold, N; Hogervorst, FBL; Honisch, E; Hopper, JL; Hulick, PJ; Investigators, K; Investigators, H; Izatt, L; Jager, A; James, P; Janavicius, R; Jensen, UB; Jensen, TD; Johannsson, OT; John, EM; Joseph, V; Kang, E; Kast, K; Kiiski, JI; Kim, S-W; Kim, Z; Ko, K-P; Konstantopoulou, I; Kramer, G; Krogh, L; Kruse, TA; Kwong, A; Larsen, M; Lasset, C; Lautrup, C; Lazaro, C; Lee, J; Lee, JW; Lee, MH; Lemke, J; Lesueur, F; Liljegren, A; Lindblom, A; Llovet, P; Lopez-Fernández, A; Lopez-Perolio, I; Lorca, V; Loud, JT; Ma, ESK; Mai, PL; Manoukian, S; Mari, V; Martin, L; Matricardi, L; Mebirouk, N; Medici, V; Meijers-Heijboer, HEJ; Meindl, A; Mensenkamp, AR; Miller, C; Gomes, DM; Montagna, M; Mooij, TM; Moserle, L; Mouret-Fourme, E; Mulligan, AM; Nathanson, KL; Navratilova, M; Nevanlinna, H; Niederacher, D; Nielsen, FCC; Nikitina-Zake, L; Offit, K; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Ott, C-E; Palli, D; Park, SK; Parsons, MT; Pedersen, IS; Peissel, B; Peixoto, A; Pérez-Segura, P; Peterlongo, P; Petersen, AH; Porteous, ME; Pujana, MA; Radice, P; Ramser, J; Rantala, J; Rashid, MU; Rhiem, K; Rizzolo, P; Robson, ME; Rookus, MA; Rossing, CM; Ruddy, KJ; Santos, C; Saule, C; Scarpitta, R; Schmutzler, RK; Schuster, H; Senter, L; Seynaeve, CM; Shah, PD; Sharma, P; Shin, VY; Silvestri, V; Simard, J; Singer, CF; Skytte, A-B; Snape, K; Solano, AR; Soucy, P; Southey, MC; Spurdle, AB; Steele, L; Steinemann, D; Stoppa-Lyonnet, D; Stradella, A; Sunde, L; Sutter, C; Tan, YY; Teixeira, MR; Teo, SH; Thomassen, M; Tibiletti, MG; Tischkowitz, M; Tognazzo, S; Toland, AE; Tommasi, S; Torres, D; Toss, A; Trainer, AH; Tung, N; van Asperen, CJ; van der Baan, FH; van der Kolk, LE; van der Luijt, RB; van Hest, LP; Varesco, L; Varon-Mateeva, R; Viel, A; Vierstrate, J; Villa, R; von Wachenfeldt, A; Wagner, P; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Wieme, G; Yadav, S; Yannoukakos, D; Yoon, S-Y; Zanzottera, C; Zorn, KK; D'Amico, AV; Freedman, ML; Pomerantz, MM; Chenevix-Trench, G; Antoniou, AC; Neuhausen, SL; Ottini, L; Nielsen, HR; Rebbeck, TR (2020-02)
    Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer ...
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. 

    Mavaddat, N; Antoniou, AC; Mooij, TM; Hooning, MJ; Heemskerk-Gerritsen, BA; GENEPSO; Noguès, C; Gauthier-Villars, M; Caron, O; Gesta, P; Pujol, P; Lortholary, A; EMBRACE; Barrowdale, D; Frost, D; Evans, DG; Izatt, L; Adlard, J; Eeles, R; Brewer, C; Tischkowitz, M; Henderson, A; Cook, J; Eccles, D; HEBON; van Engelen, K; Mourits, MJE; Ausems, MGEM; Koppert, LB; Hopper, JL; John, EM; Chung, WK; Andrulis, IL; Daly, MB; Buys, SS; kConFab Investigators; Benitez, J; Caldes, T; Jakubowska, A; Simard, J; Singer, CF; Tan, Y; Olah, E; Navratilova, M; Foretova, L; Gerdes, A-M; Roos-Blom, M-J; Van Leeuwen, FE; Arver, B; Olsson, H; Schmutzler, RK; Engel, C; Kast, K; Phillips, K-A; Terry, MB; Milne, RL; Goldgar, DE; Rookus, MA; Andrieu, N; Easton, DF; IBCCS; kConFab; BCFR (2020-01-16)
    BACKGROUND:The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially ...
  • Health-related quality of life around the time of diagnosis in patients with bladder cancer. 

    Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; Bryan, RT; Wesselius, A; Zeegers, MP (2019-12)
    OBJECTIVES:To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30. METHODS:From ...

View more